Navigation Links
NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen
Date:11/12/2008

itric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, widespread eye diseases and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of NicOx S.A. to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on NicOx S.A.'s website (http://www.nicox.com).

http://www.nicox.com


'/>"/>
SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

679

GOOD

Page: 1 2 3

Related biology technology :

1. NicOx Reports Results for the First Three Quarters of 2008
2. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
3. NicOx Announces Departure of Damian Marron for CEO Position
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
6. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
7. NicOx Opens U.S. Headquarters in New Jersey
8. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
9. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
10. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
11. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/22/2014)... Chicago, Illinois (PRWEB) December 22, 2014 ... representing tenants and occupiers of commercial real estate, has ... two new offices in Perth and Brisbane, Western Australia, ... board of directors. , ITRA Global / ACORPP ... and totally independent consultancy company providing property services to ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... , , , , , , , , ... -- NeoStem, Inc.,(NYSE Amex: NBS ) ("NeoStem" or the "Company"), ... , announced,today that it priced a public offering of 5,000,000 shares ... from the offering, after underwriting,discounts and commissions and expenses, will be ...
... , , , , ... 3SBio Inc. ( SSRX),("3SBio" or "the Company"), a leading China ... its unaudited financial results,for the fourth quarter and full year ended ... Financial Highlights:, -- Total net revenues in 2009 increased ...
... growth call for sweeping changes in how the world produces ... including an expert in plant genetics at the University of ... science and technology adviser to Secretary of State Hillary Clinton, ... popular biases against the use of agricultural biotechnology," as well ...
Cached Biology Technology:NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 2NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 3NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 23SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 33SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 43SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 53SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 63SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 73SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 83SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 93SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 103SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 113SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 123SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 133SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 143SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 153SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 163SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 173SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 183SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 193SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 203SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 213SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 223SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 233SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 243SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 253SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results 26Dramatic changes in agriculture needed as world warms and grows, researchers say 2
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... available in German . Leaf beetles fascinate ... coloring. Their larvae, however, are dangerous plant pests. Larvae of ... tree species: willow and birch. To fend off predator attacks, ... whose precursors they ingest with their leafy food. Scientists ...
... animals, their genes, and their ecosystems (such as rainforests ... than the last mass extinction 65 million years ago. ... that exist today are estimated to be extinct by ... integral part of this extensive network of life. We ...
... This release is available in French . ... today on the grounds of the Botanical Garden. The new ... the Botanical Garden and the Montral Insectarium, two Espace pour ... facilities for research into biodiversity, its preservation and its promotion. ...
Cached Biology News:Host change alters toxic cocktail 2Host change alters toxic cocktail 3Earth's biodiversity: What do we know and where are we headed? 2Earth's biodiversity: What do we know and where are we headed? 3The University of Montreal Biodiversity Centre opens 2The University of Montreal Biodiversity Centre opens 3
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... for cryogenic vials. Racks ... stainless steel boxes for 2ml, ... Vapor phase or Liquid ... risers to be ordered separately ...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Mouse TREM-2 Affinity Purified Polyclonal Ab...
Biology Products: